GIP / GLP-1 / Glucagon Tri-Agonist
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide classified as a GIP / GLP-1 / glucagon triple-receptor agonist. Vault Peptides supplies it solely as an analytical-grade biochemical reference standard for in-vitro laboratory research, assay development, and analytical method validation. It is not a drug, supplement, or consumer product.
Molecular Profile
Retatrutide is a single-chain synthetic peptide that, in receptor-pharmacology research, is characterised against the GIP, GLP-1, and glucagon receptor families. As a reference material it is used to study receptor identity, binding, and signalling pathways at the bench. Vault Peptides makes no representation regarding any biological effect in humans or animals.
Laboratory Research Applications
As an analytical reference standard, Retatrutide is used by academic, biotech, and contract-research laboratories for in-vitro work such as receptor-binding assays, analytical method development, chromatography calibration, and mass-spectrometry reference comparison. All described uses are bench/in-vitro research only.
Analytical Specifications
Supplied as a lyophilised powder with a purity specification of ≥ 99% determined by HPLC, with identity confirmed by mass spectrometry. A batch-specific Certificate of Analysis (COA) is available on request and documents purity, identity, and batch number for each lot.
Handling & Storage
For laboratory handling only. Store the lyophilised reference standard at 2–8°C, protected from light. Reconstitution and handling should follow the receiving laboratory's standard operating procedures. Not for human or animal use.
Research Disclaimer: Retatrutide is supplied strictly as an analytical/laboratory reference material for in-vitro research use only. It is NOT a drug, food, supplement, or medical product, is NOT for human or animal consumption, and no therapeutic, diagnostic, or clinical use is intended or implied. This content is technical reference information for qualified researchers.